Quantum Discovery
Quantum Discovery Labs is a technology based drug discovery company. We develop a unique computational drug discovery platform (QUANTUM), provide drug discovery services, and pursue our own in-house drug discovery projects searching for novel compounds with anti-bacterial, anti-viral and anti-cancer efficacy.
Quantum@linkedin.com
Contacts: office@q-pharm.com or comment any post on the site. You are welcome!
Quantum on Google+Categories
- absorbtion (3)
- active transport (2)
- ADME (4)
- antibiotics (2)
- antiviral (6)
- bioavailability (3)
- cancer (5)
- cardiotoxicity (1)
- collaboration (13)
- compound libraries (1)
- COPD (1)
- docking (13)
- drug design (8)
- drug discovery platform (1)
- druglikeness (4)
- false positive (3)
- flue (4)
- Generalized Born (15)
- GPCR (1)
- HERG (6)
- HIV (3)
- HIV-1 integrase (1)
- HSV (1)
- human neutrophil elastase (1)
- IC50 (18)
- inflammation (3)
- influenza (3)
- kinase (1)
- LD50 (2)
- logP (1)
- matrix proteins (2)
- mechanism of action exploration (2)
- MRDD (3)
- new therapeutic uses (1)
- oncology (4)
- openbabel (3)
- PDK1 (1)
- polar liquid (17)
- publications (12)
- q-Mol (1)
- QSAR (1)
- Quantum Software (11)
- RecA (1)
- scoring (1)
- selectivity (3)
- solvation energy (19)
- ss DNA (1)
- talk (5)
- toxicity (7)
- trombine (2)
- tuberculosis (4)
- Uncategorized (5)
- video (3)
- water (20)
Recent comments
- Vladimir Chupakhin on Solubility in water/DMSO prediction
- Nbarnes25 on Quantum Discovery Services
- New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1 on Influenza matrix M1 protein inhibitors show promising in-vivo efficacy
- Anonymous on Water polarization and density profiles at a gas-liquid interface
- Anonymous on New inhibitors of RecA (bacterial SOS response system) identified.
drug design Archive
-
Quantum tests a novel targeted anti-tuberculosis compound
Posted on June 5, 2010 | No CommentsThe situation with drug resistant forms of tuberculosis (TB), aka MDR and XDR forms, remains increasingly troubling. XDR form was originally identified in 2006 and by now comprising up to... -
Drug Discovery: identifying potential therapeutics that inhibit opioids-induced glial cell activation
Posted on February 5, 2010 | No CommentsPain remains a significant public health issue with two-thirds of patients achieving little to no pain relief from the myriad of currently available pharmacotherapies and dosing regimens. The use of... -
Experimental siRNA complex uptake without transfection reagents
Posted on November 12, 2009 | 1 CommentNormally siRNA do not penetrate cell membranes without transfection reagents. In Quantum Pharmaceutical we developed a new nanoscale complex with ability to transport siRNA over cell membranes of a cancer...


